LOGIN-VSI
29.7.2020 14:32:11 CEST | Business Wire | Press release
HTG – Howell Technology Group, the specialised supplier of innovative IT and security solutions, today announced that it has signed a supplier agreement with Login VSI , the company dedicated to maximising the end-user experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200729005078/en/
Delivered through a customer-centric approach, HTG’s professional and trusted IT consulting services enables customers to operate sustainably and achieve efficiencies gained from transformation of their IT environments to modern, cloud-based workspaces.
This partnership will focus on the provision of specialist solutions and services as part of the ecosystem for Windows Virtual Desktop (WVD). Working closely with Microsoft as a Gold partner, HTG is already deploying WVD to some impressive accounts as a cloud-based, remote working solution. Adding Login VSI to this mix represents an opportunity for HTG to join forces with the market leader in synthetic user testing.
Kevin Howell, CTO, HTG said, “Sizing end-user compute solutions to deliver optimal user experience and performance can be complex. Using Login VSI allows us to deliver our services in a performant and efficient manner.”
For Login VSI, this partnership represents the opportunity to work with a highly regarded consultant. Using their specialised skills, HTG will be able to efficiently deploy Login Enterprise into their customer base – delivering to them application compatibility testing, load testing, as well as performance and availability testing in a single platform.
Since the onset of COVID, there has been an increased demand for enterprise IT organisations to support a global remote working model. Testing of a scaled-up remote infrastructure has therefore become critical. Login VSI provides comprehensive testing and validation of the entire technology stack, from the core to the endpoint. It maximises the scalability and availability of applications and virtual desktop environments, including cloud. Login Enterprise, Login VSI’s flagship product, enables enterprises to quickly identify potential performance or availability issues by measuring and comparing application load times and application responsiveness. It is this expertise that will provide added value to HTG’s services within the digital workspace and especially as part of the WVD ecosystem.
Graham Wight, CEO, HTG commented: “We are excited about the opportunity to work with Login VSI. With the recent shift in demand for technologies that enable the smooth and secure transition to remote working, there is a greater need for performance and availability testing. The addition of this service under the partnership can only enhance and add value to the services we provide our customers.”
“We are excited about the opportunity to work with HTG,” said Eric-Jan van Leeuwen, CEO of Login VSI. “Given the global shift to remote working, there is a greater need for performance and availability testing, in order to ensure business continuity. With HTG’s superior knowledge of the WVD market and the unrivalled experience they have, we believe this is the beginning of a long-lasting relationship.”
About HTG
HTG is a leading global IT solutions company offering a range of disruptive technologies and best in class products. We work closely with customers from a wide range of industries to enable efficiencies through transformation of their IT environments and help simplify the way our IT services are delivered to them. Our digital knowledge and expertise in the latest technologies enables us to help our customers define their digital vision and strategic roadmap, delivering real and impactful change.
For further information please visit www.htguk.com or contact us on 0191 481 3446 .
About Login VSI
Login VSI is the only solution in the market guaranteed to maximize the end-user experience for digital workspaces. We reduce risk and ensure business continuity by safeguarding application and desktop performance. We do this using synthetic users to automatically test and validate the impact of change in physical, virtual and cloud-based workspaces.
Our flagship product, Login Enterprise integrates application compatibility testing, load testing, as well as performance & availability testing into a single platform. Login Enterprise also includes standard “out-of-the-box” application template workloads. Login VSI has over 400 customers in 50 countries. For more information, visit www.loginvsi.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005078/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
